Data Insights

Atezolizumab by F. Hoffmann-La Roche for Vulvar Cancer: Likelihood of Approval

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Vulvar Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Vulvar Cancer

Data Insights

Atezolizumab by F. Hoffmann-La Roche for Rectal Cancer: Likelihood of Approval

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Rectal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Rectal Cancer

Data Insights

Atezolizumab by F. Hoffmann-La Roche for Chondrosarcoma: Likelihood of Approval

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Chondrosarcoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Chondrosarcoma

Data Insights

Atezolizumab by F. Hoffmann-La Roche for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Human Epidermal Growth Factor Receptor...

Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

Data Insights

Atezolizumab by F. Hoffmann-La Roche for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction....

Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Adenocarcinoma Of The Gastroesophageal Junction

Data Insights

Atezolizumab by F. Hoffmann-La Roche for Neuroendocrine Cancer: Likelihood of Approval

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Neuroendocrine Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Neuroendocrine Cancer

Data Insights

Atezolizumab by F. Hoffmann-La Roche for Lung Cancer: Likelihood of Approval

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Lung Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Lung Cancer

Data Insights

Atezolizumab by F. Hoffmann-La Roche for Cutaneous Squamous Cell Carcinoma (cSCC): Likelihood of Approval

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Cutaneous Squamous Cell Carcinoma (cSCC)....

Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Cutaneous Squamous Cell Carcinoma (cSCC)

Data Insights

Atezolizumab by F. Hoffmann-La Roche for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Human Epidermal Growth Factor Receptor...

Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)

Data Insights

Atezolizumab by F. Hoffmann-La Roche for Breast Cancer: Likelihood of Approval

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Breast Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Breast Cancer

Data Insights

Atezolizumab by F. Hoffmann-La Roche for Ureter Cancer: Likelihood of Approval

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Ureter Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Ureter Cancer

Data Insights

Atezolizumab by F. Hoffmann-La Roche for Anal Cancer: Likelihood of Approval

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Anal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Anal Cancer

Data Insights

Atezolizumab by F. Hoffmann-La Roche for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According...

Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Gastroesophageal (GE) Junction Carcinomas

Data Insights

Atezolizumab by F. Hoffmann-La Roche for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell...

Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)

Data Insights

Atezolizumab by F. Hoffmann-La Roche for Gastric Cancer: Likelihood of Approval

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Gastric Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Gastric Cancer

Data Insights

Atezolizumab by F. Hoffmann-La Roche for Ureter Cancer: Likelihood of Approval

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Ureter Cancer. According to GlobalData,...

Data Insights

Atezolizumab by F. Hoffmann-La Roche for Anal Cancer: Likelihood of Approval

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Anal Cancer. According to GlobalData,...

Data Insights

Atezolizumab by F. Hoffmann-La Roche for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According...

Data Insights

Atezolizumab by F. Hoffmann-La Roche for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell...

Data Insights

Atezolizumab by F. Hoffmann-La Roche for Gastric Cancer: Likelihood of Approval

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Gastric Cancer. According to GlobalData,...